SKIN.SW Cassiopea S.p.A. (SIX) +9.85% intraday: rising volume supports further moves

SKIN.SW stock rallied intraday to CHF35.70, up 9.85% on volume of 2,756 shares as traders reacted to higher-than-average flows on the SIX exchange in Switzerland. The move lifted the day high to CHF36.00 from an open of CHF32.00, with relative volume at 1.52x the 50-day average. This intraday surge marks SKIN.SW as a high-volume mover in the Healthcare/Biotechnology space and warrants a closer look at fundamentals, technicals, and model forecasts for near-term trading decisions.

Intraday price and volume snapshot for SKIN.SW stock

Cassiopea S.p.A. (SKIN.SW) traded between CHF32.00 and CHF36.00 intraday on 17 Mar 2026, closing the session around CHF35.70 on the SIX exchange in Switzerland. Volume reached 2,756 versus an average of 1,818, signalling real buying interest for a small-cap biotech.
Relative volume of 1.52 suggests the move is meaningful for this liquidity profile and explains the 9.85% price gain versus the previous close of CHF32.50.

Fundamentals and valuation: SKIN.SW stock in context

Cassiopea reports EPS of -1.269 and a negative PE around -28.13, reflecting continued clinical-stage spending. Price averages sit at CHF34.37 (50-day) and CHF37.22 (200-day). Book value per share is 1.50 and cash per share is 0.25, while the current ratio is 1.98, indicating adequate short-term liquidity for now.
Compared with the broader Healthcare sector average PE of 29.45, SKIN.SW’s negative earnings and early-stage pipeline keep it valued as a speculative biotech play rather than a cash-flow generator.

Pipeline and catalysts driving SKIN.SW stock momentum

Cassiopea focuses on medical dermatology with assets including Winlevi and Breezula in late-stage studies. Clinical readouts, regulatory updates, or partnering news are typical catalysts for the stock given the company’s biotech profile.
Traders should watch press releases from Cassiopea and any SIX filings—positive clinical or commercial updates often produce quick volume spikes and price re-rating for peers in the Biotechnology industry.

Technical and trading metrics influencing SKIN.SW stock

Short-term technicals show the stock above its 50-day average (CHF34.37) but below the 200-day (CHF37.22). Day range and volume suggest a short-term breakout attempt; year high is CHF53.00 and year low CHF25.70, giving a broad trading band.
Active traders should note the stock’s limited liquidity: average daily volume 1,818 shares. Wider spreads and lower market depth increase execution risk for larger positions.

Meyka grade and model-based outlook for SKIN.SW stock

Meyka AI rates SKIN.SW with a score out of 100: 62.57/100 — Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This grade is informational and not investment advice.
Meyka AI’s forecast model projects a 12-month base target of CHF42.00. Versus the current price of CHF35.70, that implies an upside of +17.65%. The model also outlines a conservative bear target of CHF28.00 (-21.57%) and a bull target of CHF55.00 (+54.06%). Forecasts are model-based projections and not guarantees.

Final Thoughts

SKIN.SW stock is a clear intraday high-volume mover on 17 Mar 2026, trading CHF35.70 after a 9.85% rise on volume 2,756. The jump reflects speculative buying around Cassiopea’s dermatology pipeline and limited liquidity on the SIX exchange. Fundamentals remain early-stage: EPS -1.269, negative PE, modest cash per share 0.25, and a current ratio near 1.98. Sector peers trade at materially different valuations, so SKIN.SW’s risk-reward is driven by clinical and regulatory milestones rather than earnings stability.
Meyka AI’s forecast model projects a 12-month base target of CHF42.00, implying +17.65% upside from CHF35.70; this sits alongside a bear case at CHF28.00 and a bull case at CHF55.00. Traders and investors should weigh higher short-term volatility and limited liquidity against the potential upside from pipeline catalysts. For primary sources, see the company site and SIX exchange pages for filings and announcements: Cassiopea and SIX Swiss Exchange. Forecasts are model-based projections and not guarantees. Meyka AI provides this as an AI-powered market analysis platform.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.